218 related articles for article (PubMed ID: 27769548)
1. Characteristics and treatment of human epidermal growth factor receptor 2 positive breast cancer: 43,485 cases from the National Cancer Database treated in 2010 and 2011.
Killelea BK; Chagpar AB; Horowitz NR; Lannin DR
Am J Surg; 2017 Feb; 213(2):426-432. PubMed ID: 27769548
[TBL] [Abstract][Full Text] [Related]
2. The effect of Paget disease on axillary lymph node metastases and survival in invasive ductal carcinoma.
Wong SM; Freedman RA; Sagara Y; Stamell EF; Desantis SD; Barry WT; Golshan M
Cancer; 2015 Dec; 121(24):4333-40. PubMed ID: 26376021
[TBL] [Abstract][Full Text] [Related]
3. Comprehensive prognostic report of the Japanese Breast Cancer Society Registry in 2004.
Kinoshita T; Fukui N; Anan K; Iwamoto T; Niikura N; Kawai M; Hayashi N; Tsugawa K; Aogi K; Ishida T; Masuoka H; Masuda S; Iijima K; Nakamura S; Tokuda Y
Breast Cancer; 2016 Jan; 23(1):39-49. PubMed ID: 26446041
[No Abstract] [Full Text] [Related]
4. Impact of screening on clinicopathological features and treatment for invasive breast cancer: results of two national surveys.
Cutuli B; Dalenc F; Cottu PH; Gligorov J; Guastalla JP; Petit T; Amrate A
Cancer Radiother; 2015 Aug; 19(5):295-302. PubMed ID: 26188735
[TBL] [Abstract][Full Text] [Related]
5. Prognostic value of phosphorylated HER2 in HER2-positive breast cancer patients treated with adjuvant trastuzumab.
Kurebayashi J; Kanomata N; Yamashita T; Shimo T; Mizutoh A; Moriya T; Sonoo H
Breast Cancer; 2015 May; 22(3):292-9. PubMed ID: 23749689
[TBL] [Abstract][Full Text] [Related]
6. Relative effectiveness of adjuvant chemotherapy for invasive lobular compared with invasive ductal carcinoma of the breast.
Marmor S; Hui JYC; Huang JL; Kizy S; Beckwith H; Blaes AH; Rueth NM; Tuttle TM
Cancer; 2017 Aug; 123(16):3015-3021. PubMed ID: 28382636
[TBL] [Abstract][Full Text] [Related]
7. Tubular carcinoma of the breast: institutional and SEER database analysis supporting a unique classification.
Romano AM; Wages NA; Smolkin M; Fortune KL; Atkins K; Dillon PM
Breast Dis; 2015; 35(2):103-11. PubMed ID: 25567000
[TBL] [Abstract][Full Text] [Related]
8. [Diagnosis and treatment for Paget's breast cancer: state of the art].
Fetisova EY; Zikiryakhodhaev AD; Volchenko NN
Vopr Onkol; 2015; 61(6):908-12. PubMed ID: 26995977
[TBL] [Abstract][Full Text] [Related]
9. Human epidermal growth factor receptor-2 positivity predicts locoregional recurrence in patients with T1-T2 breast cancer.
Cefaro GA; Genovesi D; Trignani M; DI Nicola M
Anticancer Res; 2014 Mar; 34(3):1207-12. PubMed ID: 24596361
[TBL] [Abstract][Full Text] [Related]
10. Histopathological features of breast cancer in Al-Madinah region of Saudi Arabia.
Albasri A; Hussainy AS; Sundkji I; Alhujaily A
Saudi Med J; 2014 Dec; 35(12):1489-93. PubMed ID: 25491214
[TBL] [Abstract][Full Text] [Related]
11. Breast-Conserving Surgery in Patients With Mammary Paget's Disease.
Yao Y; Sun L; Meng Y; Zhuang Y; Zhao L; Yu Q; Si C
J Surg Res; 2019 Sep; 241():178-187. PubMed ID: 31026796
[TBL] [Abstract][Full Text] [Related]
12. [Comparative immunohistochemical study of invasive duct carcinoma and Paget's disease of the breast with c-erbB-2 overexpression].
Petrov SV; Raskin GA; Khasanov RSh; Tsyplakov DE
Arkh Patol; 2006; 68(5):10-4. PubMed ID: 17144522
[TBL] [Abstract][Full Text] [Related]
13. [Prognostic value of estrogen receptor, progesterone receptor and human epidermal growth factor receptor-2 in node positive breast cancer patients treated by mastectomy].
Wang SL; Li YX; Song YW; Wang WH; Jin J; Liu YP; Liu XF; Yu ZH
Zhonghua Zhong Liu Za Zhi; 2010 Jul; 32(7):520-5. PubMed ID: 21029696
[TBL] [Abstract][Full Text] [Related]
14. Treatment patterns of elderly breast cancer patients at two Canadian cancer centres.
Angarita FA; Chesney T; Elser C; Mulligan AM; McCready DR; Escallon J
Eur J Surg Oncol; 2015 May; 41(5):625-34. PubMed ID: 25727372
[TBL] [Abstract][Full Text] [Related]
15. Is there a low-grade precursor pathway in breast cancer?
King TA; Sakr RA; Muhsen S; Andrade VP; Giri D; Van Zee KJ; Morrow M
Ann Surg Oncol; 2012 Apr; 19(4):1115-21. PubMed ID: 21935747
[TBL] [Abstract][Full Text] [Related]
16. Is breast cancer from Sub Saharan Africa truly receptor poor? Prevalence of ER/PR/HER2 in breast cancer from Kenya.
Sayed S; Moloo Z; Wasike R; Bird P; Oigara R; Govender D; Kibera J; Carrara H; Saleh M
Breast; 2014 Oct; 23(5):591-6. PubMed ID: 25012047
[TBL] [Abstract][Full Text] [Related]
17. The Effect of Molecular Subtype and Residual Disease on Locoregional Recurrence in Breast Cancer Patients Treated with Neoadjuvant Chemotherapy and Postmastectomy Radiation.
Yang TJ; Morrow M; Modi S; Zhang Z; Krause K; Siu C; McCormick B; Powell SN; Ho AY
Ann Surg Oncol; 2015 Dec; 22 Suppl 3(Suppl 3):S495-501. PubMed ID: 26130454
[TBL] [Abstract][Full Text] [Related]
18. Paget's disease of the breast: the experience of the European Institute of Oncology and review of the literature.
Caliskan M; Gatti G; Sosnovskikh I; Rotmensz N; Botteri E; Musmeci S; Rosali dos Santos G; Viale G; Luini A
Breast Cancer Res Treat; 2008 Dec; 112(3):513-21. PubMed ID: 18240020
[TBL] [Abstract][Full Text] [Related]
19. Clinicopathological significance of HER2/neu genetic heterogeneity in HER2/neu non-amplified invasive breast carcinomas and its concurrent axillary metastasis.
Shafi H; Astvatsaturyan K; Chung F; Mirocha J; Schmidt M; Bose S
J Clin Pathol; 2013 Aug; 66(8):649-54. PubMed ID: 23539740
[TBL] [Abstract][Full Text] [Related]
20. Influence of neoadjuvant chemotherapy on HER2/neu status in invasive breast cancer.
Li P; Liu T; Wang Y; Shao S; Zhang W; Lv Y; Yi J; Wang Z
Clin Breast Cancer; 2013 Feb; 13(1):53-60. PubMed ID: 23103368
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
